309 related articles for article (PubMed ID: 29940089)
41. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
42. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Kamphuisen PW; Lee AYY; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
J Thromb Haemost; 2018 Jun; 16(6):1069-1077. PubMed ID: 29573330
[TBL] [Abstract][Full Text] [Related]
43. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Agnelli G; Hoffmann U; Hainaut P; Gaine S; Ay C; Coppens M; Schindewolf M; Jimenez D; Brüggenjürgen B; Levy P; Laeis P; Fronk EM; Zierhut W; Malzer T; Manu MC; Reimitz PE; Bramlage P; Cohen AT;
Thromb Res; 2020 Dec; 196():297-304. PubMed ID: 32950897
[TBL] [Abstract][Full Text] [Related]
44. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
[TBL] [Abstract][Full Text] [Related]
45. Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP; Ruff CT; Braunwald E; Murphy SA; Wiviott SD; Halperin JL; Waldo AL; Ezekowitz MD; Weitz JI; Špinar J; Ruzyllo W; Ruda M; Koretsune Y; Betcher J; Shi M; Grip LT; Patel SP; Patel I; Hanyok JJ; Mercuri M; Antman EM;
N Engl J Med; 2013 Nov; 369(22):2093-104. PubMed ID: 24251359
[TBL] [Abstract][Full Text] [Related]
46. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
48. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
49. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Schulman S; Kearon C; Kakkar AK; Mismetti P; Schellong S; Eriksson H; Baanstra D; Schnee J; Goldhaber SZ;
N Engl J Med; 2009 Dec; 361(24):2342-52. PubMed ID: 19966341
[TBL] [Abstract][Full Text] [Related]
50. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
[TBL] [Abstract][Full Text] [Related]
52. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
[TBL] [Abstract][Full Text] [Related]
53. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
54. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
55. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
56. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
57. Edoxaban: an update on the new oral direct factor Xa inhibitor.
Bounameaux H; Camm AJ
Drugs; 2014 Jul; 74(11):1209-31. PubMed ID: 25034361
[TBL] [Abstract][Full Text] [Related]
58. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
[TBL] [Abstract][Full Text] [Related]
59. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
60. Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Yamazaki H; Yagi S; Torii Y; Amano R; Oomichi Y; Sangawa T; Fukuda D; Kadota M; Ise T; Ueno R; Hara T; Kusunose K; Matsuura T; Tobiume T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Akaike M; Sata M
J Cardiol; 2018 Mar; 71(3):305-309. PubMed ID: 29100817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
